Shigellosis is a relatively uncommon disease in the EU/EEA, but remains of concern in some countries and for some population groups. For 2020, 29 EU/EEA countries reported 1 806 confirmed shigellosis cases.
In 2020, 13 914 cases of hepatitis C were reported in 28 EU/EEA Member States. Excluding countries that only reported acute cases leaves 13 901 cases, which corresponds to a crude rate of 3.9 cases per 100 000 population.
This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.
This document assesses the risk of further spread of S. sonnei amongst MSM and in the broader population in EU/EEA countries, resulting from the current increase in extensively-drug resistant S. sonnei infections.
In 2019, 37 733 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases leaves 37 660 cases, which corresponds to a crude rate of 8.9 cases per 100 000 population.
In order to monitor progress towards the United Nations Sustainable Development Goals 2030 target to combat viral hepatitis, this report provides data on hepatitis B and C prevention, incidence, diagnosis, treatment, cure/viral suppression, and mortality in European Union/European Economic Area (EU/EEA) countries with data collected in 2019.
This report of the EFSA and ECDC presents the results of zoonoses monitoring activities carried out in 2019 in 36 European countries (28 Member States (MS) and eight non-MS).